Plasma Insulin/Erythrocytic Aldose Reductase Ratio as a Predictor for Hepatocellular Carcinoma among Type II Diabetics and Hepatitis C Virus-infected Patients.
| Autor: | Abdel-Hamid NM; Department of Biochemistry, Faculty of Pharmacy, Kafrelsheikh University, Egypt., Sherif MH; Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt., Al Samahy AE; Biochemistry Division, Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt., Abdelhamid MS; Biochemistry Division, Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2022 Nov 01; Vol. 23 (11), pp. 3815-3823. Date of Electronic Publication: 2022 Nov 01. |
| DOI: | 10.31557/APJCP.2022.23.11.3815 |
| Abstrakt: | Background: Hepatocellular carcinoma (HCC) is a possible oncogenic progression during persistent hepatitis C-infection +/- type II diabetes mellitus (DM). We aim to investigate the plasma insulin, erythrocytic aldose reductase (AR) and sorbitol dehydrogenase (SDH) as possible predictive tools for HCC in hepatitis C-infected patients (HCV) +/- DM. Erythrocytes (RBCs) were adopted as a possible vehicle for pre-malignant variations being of short life span. Methods: The study included 20 healthy control and 100 patients of 48-64 years old, divided into 5 equal groups as; type II DM, HCC, HCC with DM, DM- HCV infected and non-DM HCV infected. Plasma levels of AFP and insulin were measured. Results: It showed an elevated AR, significant reduction of SDH in RBCs and plasma of DM patients. These values were greatly elevated among HCV, HCC, diabetic HCV, and diabetic HCC patients. All DM patients showed elevated insulin levels than normoglycemic controls. Conclusion: The study substantiated the use of RBCs as a vehicle for early diagnostic markers better than plasma. We recommend the use of insulin/ erythrocytic AR ratio as a new laboratory marker for predicting HCC among type II diabetics or non-treated HCV-infected patients with control insulin/ erythrocytic AR ratio by each laboratory. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|